Drug intelligence / Profile preview

Flu Care

Development stage: Unknown
Lead developer: Composite Interceptive Med Science
Administration: Intramuscular, Intranasal, Intradermal, Oral, Inhalation, Intravenous

Overview

Flu Care is a polyherbal formulation developed by Composite Interceptive Med Science. It is being investigated for its efficacy in the management of acute uncomplicated influenza when administered within 48 hours of symptom onset. Each dose of Flu Care contains 350 mg of polyherbal components.

Brand names: Flu Care

Beyond the preview

Go deeper on Flu Care.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flu Care.

Explore the full profile